Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pralsetinib - Blueprint Medicines

Drug Profile

Pralsetinib - Blueprint Medicines

Alternative Names: BLU-667; CS 3009; GAVRETO; Gavreto; Pratinib; Pujihua; RG 6396

Latest Information Update: 26 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blueprint Medicines
  • Developer Blueprint Medicines; CStone Pharmaceuticals; Roche
  • Class Amides; Amines; Antineoplastics; Cyclohexanes; Ethers; Fluorinated hydrocarbons; Pyrazoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c ret inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Thyroid cancer
  • Phase II Solid tumours

Most Recent Events

  • 22 Feb 2024 Blueprint terminates its licence for GAVRETO
  • 22 Feb 2024 Rigel Pharmaceuticals entered into a definative agreement with Blueprint Medicines to acquired the US rights of GAVRETO® (pralsetinib) from Blueprint Medicines
  • 04 Jan 2024 Roche withdraws a phase III trial in Thyroid cancer (First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In adults, In adolescents, In the elderly) in Spain, Portugal, France, Italy, Netherlands, Greece, Germany, Poland, Denmark, Sweden, Bulgaria (PO) prior to enrolment due to several logistical challenges during start-up (NCT04760288) (EudraCT2020-005269-15)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top